Advanced Imaging Reveals Metastasis

This is a news story, published by ScienceDaily, that relates primarily to EMBARK news.

EMBARK news

For more EMBARK news, you can click here:

more EMBARK news

biology news

For more biology news, you can click here:

more biology news

ScienceDaily news

For more news from ScienceDaily, you can click here:

more news from ScienceDaily

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best science news, business news, entertainment news, and much more. If you like biology news, you might also like this article about

prostate cancer imaging

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest risk prostate cancer patients news, sensitive prostate cancer news, biology news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

prostate cancer staging

ScienceDaily

•

Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases

Summary

Nutrition label

80% Informative

Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases.

Findings could impact the interpretation of previous clinical trial results, including the EMBARK trial, which relied on standard imaging.

PSMA-PET imaging uses tiny amounts of radioactive "tracers" called radiotracers, that binds to prostate cancer cells, making them visible on PET scans.

Adrien Holzgreve , Wesley R. Armstrong , Kevyn J. Clark , Matthias R. Benz , Clayton P. Smith , Loïc Djaileb , Andrei Gafita , Pan Thin , Nicholas G. Nickols , Amar U. Kishan , Matthew B. Rettig , Robert E. Reiter and Jeremie Calais .